Nephrology Companies

Developer of implantable battery-powered pump for removal of ascites. It has developed a pump technology which can have application across multiple disease areas. The first product alfapump is an implantable pump system that collects ascites as they form and moves them into the bladder. The pump can be charged wirelessly through the skin. Future applications include chronic pleural effusion and fluid overload due to congestive heart failure or renal disease.

Developing therapeutics solutions to treat patients with kidney disease. The company's lead candidate is Vafseo is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.

Developer of therapeutics for the gastrointestinal tract, cardio-renal, GI, and metabolic diseases. Its lead product, Tenapanor (RDX5791), a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and hyperphosphatemia in chronic kidney disease patients on dialysis. Also developing RDX002, treatment of high potassium, or hyperkalemia, in kidney and heart disease patients.

Developer of antibody therapeutics for treating oncology and neurodegenerative conditions. This organization identifies drug targets by analyzing patient antibody repertoires through deep sequencing and computational analysis. The process focuses on identifying convergent protective antibody responses found in individuals who demonstrate resilience to specific diseases. These findings facilitate the creation of therapeutic candidates intended for clinical application.